Published: 29 August 2021
Author(s): Lucia Taramasso, Laura Magnasco, Federica Portunato, Federica Briano, Antonio Vena, Daniele R. Giacobbe, Chiara Dentone, Chiara Robba, Lorenzo Ball, Maurizio Loconte, Nicolò Patroniti, Paolo Frisoni, Raffaele D'Angelo, Silvia Dettori, Malgorzata Mikulska, Paolo Pelosi, Matteo Bassetti
Issue: January 2022
Section: Original Article

Tocilizumab is a recombinant humanized monoclonal antibody developed against soluble and membrane-bound isoforms of the interleukin-6 [IL-6] receptor. It prevents the binding of IL-6 to its receptor, thus inhibiting the IL-6 inflammatory cascade [1]. In the first phase of the severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2] pandemic [2,3], tocilizumab has been proposed to counteract the cytokine release syndrome observed in the severe forms of the SARS-CoV-2 disease [COVID-19] [1,4].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.